BioSpace News Archive

Business

Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights

Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments

May 7, 2020
·
6 min read
Business

Cryoport Revenue Grows 47% for First Quarter 2020

Revenue from commercial therapies increased 110% over the prior year

May 7, 2020
·
13 min read
Business

Provention Bio Reports First Quarter 2020 Financial Results and Provides Business Update

Company on Track to Complete Submission of Rolling Biologics License Application for Teplizumab in Q4 2020

May 7, 2020
·
8 min read
Business

CTI BioPharma Reports First Quarter 2020 Financial Results

CTI BioPharma Corp. reported its financial results for the first quarter ended March 31, 2020.

May 7, 2020
·
5 min read
Business

PDL BioPharma Reports 2020 First Quarter Financial Results

PDL BioPharma, Inc. reports financial results for the three months ended March 31, 2020 and provides a business update

May 7, 2020
·
15 min read
Business

Personalis Reports First Quarter 2020 Financial Results

Personalis, Inc., a leader in advanced genomics for cancer, reported financial results for the first quarter ended March 31, 2020.

May 7, 2020
·
5 min read
Business

Puma Biotechnology Reports First Quarter 2020 Financial Results

Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2020.

May 7, 2020
·
14 min read
Business

Sage Therapeutics Announces First Quarter 2020 Financial Results and Highlights Pipeline and Business Progress

Expected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications

May 7, 2020
·
22 min read
Biotech Beach

Pushing Rare Disease Drug Development Forward Despite COVID-19

Global Genes to Host RARE Drug Development Symposium Virtual Event

May 7, 2020
·
2 min read
Business

ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO

For the first quarter 2020, ANI reports: Net revenues of $49.8 million versus $52.9 million in 2019 GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59 Adjusted non-GAAP EBITDA of $17.6 million Adjusted non-GAAP diluted earnings per share of $1.04 Integrates Amerigen Pharmaceuti

May 7, 2020
·
20 min read